ArticleThe American journal of emergency medicine2016
Plasma bioactive adrenomedullin as a prognostic biomarker in acute heart failure.
Article in The American journal of emergency medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Role of Adrenomedullin as a Prognostic Biomarker in Acute Heart Failure Patients: A Systematic Review and Meta-Analysis.Cardiology · 2026Pooled it
- The role of biomarkers across the care continuum in acute heart failure.Biomarker research · 2026Review
- Association of perioperative bioactive adrenomedullin with early postoperative organ dysfunction after major hepatic resection: An exploratory observational study.Langenbeck's archives of surgery · 2026Observational
- Bio-Adrenomedullin Predicts Death and Major Adverse Cardiovascular Events in Cardiac Amyloidosis: A Cross-Continental Multicenter Study.Journal of the American Heart Association · 2026Observational
- Signs of congestion, quality of life and short-term rehospitalization in patients with heart failure.ESC heart failure · 2025Article
- Clinical Value of Bioactive Adrenomedullin and Proenkephalin A in Patients with Left Ventricular Assist Devices: An Observational Study.Journal of clinical medicine · 2025Article
- The Role of Adrenomedullin as a Predictive Marker of the Risk of Death and Adverse Clinical Events: A Review of the Literature.Journal of clinical medicine · 2024Review
- Long-Term Prognostic Value of Adipocytokines in Patients with Acute Coronary Syndrome: An 8-Year Clinical Prospective Cohort Study.Journal of inflammation research · 2024Article
- Clinical Potential of Adrenomedullin Signaling in the Cardiovascular System.Circulation research · 2023Review
- Bioactive adrenomedullin for assessment of venous congestion in heart failure.ESC heart failure · 2022Article
- Activity of the adrenomedullin system to personalise post-discharge diuretic treatment in acute heart failure.Clinical research in cardiology : official journal of the German Cardiac Society · 2022Article
- Proadrenomedullin in Patients with Preserved Left Ventricular Systolic Function Undergoing Coronary Artery Bypass Grafting.Brazilian journal of cardiovascular surgery · 2022Article
- Bioactive adrenomedullin a prognostic biomarker in patients with mild to moderate dyspnea at the emergency department: an observational study.Internal and emergency medicine · 2022Observational
- Proenkephalin A and bioactive adrenomedullin are useful for risk prognostication in cardiac surgery.Frontiers in cardiovascular medicine · 2022Article
- Observational
- Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC).European journal of heart failure · 2021Review
- Adrenomedullin: A Novel Therapeutic for the Treatment of Inflammatory Bowel Disease.Biomedicines · 2021Review
- The usefulness of plasma levels of mature and total adrenomedullin as biomarkers indicating the magnitude of surgical stress responses: A single-center, prospective, observational study.Journal of clinical and translational research · 2021Article
- Increased concentrations of bioactive adrenomedullin subsequently to angiotensin-receptor/neprilysin-inhibitor treatment in chronic systolic heart failure.British journal of clinical pharmacology · 2021Article
- The diagnostic and prognostic value of mature and total adrenomedullin for sepsis: a prospective observational study.Anaesthesiology intensive therapy · 2021Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveThe objective was to evaluate the prognostic performance of a new biomarker, plasma bioactive adrenomedullin (bio-ADM), for short-term clinical outcomes in acute heart failure.
methodsA multicenter prospective cohort study of adult emergency department (ED) patients suspected of having acute heart failure was conducted to evaluate the association between plasma bio-ADM concentration and clinical outcomes. The primary outcome was a composite of the following within 30 days: death, cardiac arrest with resuscitation, respiratory failure, emergency dialysis, acute coronary syndrome, hospitalization >5 days, and repeat ED visit or hospitalization. Prognostic accuracy was evaluated with a nonparametric receiver operating characteristic curve. In addition, a multivariable logistic regression model was constructed to assess the additive prognostic performance of bio-ADM while adjusting for other biomarkers routinely used clinically, including B-type natriuretic peptide, cardiac troponin I, creatinine, and sodium concentration.
resultsTwo hundred forty-six patients were enrolled, including 85 (34.6%) patients with the primary outcome. Plasma bio-ADM concentrations were higher among patients who experienced the primary outcome (median, 80.5 pg/mL; interquartile range [IQR], 53.7-151.5 pg/mL) compared with those who did not (median, 54.4 pg/mL; IQR, 43.4-78.4 pg/mL) (P < .01). Area under the receiver operating characteristic curve was 0.70 (95% confidence interval, 0.63-0.75). After adjusting for the other biomarkers, plasma bio-ADM remained a strong predictor of the primary outcome (adjusted odds ratio per IQR change, 2.68; 95% confidence interval, 1.60-4.51).
conclusionsBioactive adrenomedullin concentrations at the time of ED evaluation for acute heart failure were predictive of clinically important 30-day outcomes, suggesting that bio-ADM is a promising prognostic marker for further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.